The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.
Progress in an understanding of the genetic basis of cancer coupled to molecular pharmacology of potential new anticancer drugs calls for new approaches that are able to address key issues in the drug development process, including pharmacokinetic (PK) and pharmacodynamic (PD) relationships. The incorporation of predictive preclinical PK/PD models into rationally designed early-stage clinical trials offers a promising way to relieve a significant bottleneck in the drug discovery pipeline. The aim of the current review is to discuss some considerations for how quantitative PK and PD analyses for anticancer drugs may be conducted and integrated into a global translational effort, and the importance of examining drug disposition and dynamics in target tissues to support the development of preclinical PK/PD models that can be subsequently extrapolated to predict pharmacologic characteristics in patients. In this article, we describe three different physiologically based (PB) PK modeling approaches, i.e., the whole-body PBPK model, the hybrid PBPK model, and the two-pore model for macromolecules, as well as their applications. General conclusions are that greater effort should be made to generate more clinical data that could validate scaled preclinical PB-PK/PD tumor-based models and, thus, stimulate a framework for preclinical to clinical translation. Finally, given the innovative techniques to measure tissue drug concentrations and associated biomarkers of drug responses, development of predictive PK/PD models will become a standard approach for drug discovery and development.
Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New York 10029, USA.
Qingyu
Q
Zhou
James M
JM
Gallo
D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015415:Biomarkers; D015195:Drug Design; D006801:Humans; D015233:Models, Statistical; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D049490:Systems Biology; D057170:Translational Research, Biomedical
D000970:Antineoplastic Agents; D015415:Biomarkers
J Pharm Sci. 2002 May;91(5):1358-70
11977112
Br J Clin Pharmacol. 2008 Oct;66(4):485-97
18637887
Clin Cancer Res. 2004 Jun 1;10(11):3728-36
15173079
Nat Rev Cancer. 2010 Jul;10(7):514-23
20535131
Clin Cancer Res. 2006 May 15;12(10):3115-23
16707610
Br J Clin Pharmacol. 2008 Jan;65(1):110-22
17711537
J Pharm Sci. 2006 Jun;95(6):1238-57
16639716
Clin Cancer Res. 1996 Feb;2(2):359-67
9816179
Clin Cancer Res. 2005 Aug 1;11(15):5558-65
16061873
Xenobiotica. 2007 Oct-Nov;37(10-11):1295-310
17968746
J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):185-219
14571691
Clin Cancer Res. 2007 Jul 15;13(14):4271-9
17634557
Clin Pharmacol Ther. 2000 Nov;68(5):568-77
11103759
J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):373-400
17431753
J Pharm Sci. 2005 Jun;94(6):1259-76
15858854
J Pharm Sci. 1985 Oct;74(10):1097-9
3866061
J Control Release. 2010 Feb 15;141(3):265-76
19895862
Eur J Cancer. 2008 Jan;44(1):142-50
18039567
Clin Cancer Res. 2009 Nov 15;15(22):7092-8
19861433
Drug Metab Dispos. 2003 May;31(5):510-8
12695336
Clin Pharmacol Ther. 2010 Nov;88(5):660-7
20927084
Mol Cancer Ther. 2008 Feb;7(2):407-17
18281523
Eur J Cancer. 2009 Sep;45 Suppl 1:436-8
19775662
Leukemia. 2002 Jul;16(7):1213-9
12094245
Drug Discov Today. 2006 Jan;11(1-2):81-8
16478695
Drug Metab Dispos. 1985 Nov-Dec;13(6):729-39
2867880
Nat Rev Cancer. 2004 Oct;4(10):806-13
15510161
J Pharmacokinet Biopharm. 1978 Dec;6(6):487-503
731413
Pharm Res. 1993 Jul;10(7):1093-5
8378254
Drug Metab Pharmacokinet. 2009;24(1):16-24
19252333
J Clin Invest. 1948 Jul;27(4):476-83
16695568
Trends Biotechnol. 2009 May;27(5):315-28
19339067
J Pharm Sci. 2010 Mar;99(3):1582-600
19774657
Clin Pharmacol Ther. 1994 Oct;56(4):406-19
7955802
Mol Cancer Ther. 2009 Jun;8(6):1438-47
19509243
Drug Metab Dispos. 2010 Sep;38(9):1436-42
20538720
J Pharmacol Exp Ther. 2009 May;329(2):580-91
19233938
Cancer Chemother Pharmacol. 1996;38(6):499-507
8823490
J Pharmacokinet Biopharm. 1979 Apr;7(2):127-45
20218010
Nat Chem Biol. 2006 Dec;2(12):689-700
17108987
J Pharmacokinet Pharmacodyn. 2009 Apr;36(2):179-97
19387803
Eur J Cancer. 2009 Dec;45(18):3336-46
19854637
Clin Cancer Res. 2004 Dec 1;10(23):8048-58
15585640
Nature. 2009 Apr 9;458(7239):719-24
19360079
Antimicrob Agents Chemother. 2002 Jul;46(7):2219-28
12069977
Mol Cancer Ther. 2006 Jun;5(6):1550-8
16818514
Cancer Chemother Rep. 1975 Jul-Aug;59(4):795-804
1236771
ACS Nano. 2010 Nov 23;4(11):6303-17
20945925
Clin Pharmacol Ther. 2006 Aug;80(2):136-45
16890575
Br J Clin Pharmacol. 2007 Nov;64(5):622-33
17935602
J Pharm Sci. 1983 Oct;72(10):1103-27
6358460
Cancer Res. 1995 Oct 15;55(20):4611-22
7553638
Drug Metab Dispos. 2006 Jan;34(1):94-101
16221756
Pharm Res. 1991 Feb;8(2):247-53
2023876
Oncology. 1981;38(1):53-8
7443177
J Pharm Sci. 2009 May;98(5):1885-904
18803264
Cell. 2000 Jan 7;100(1):57-70
10647931
Clin Pharmacol Ther. 1995 Aug;58(2):238-40
7648775
Clin Cancer Res. 2007 May 1;13(9):2768-76
17473210
AAPS PharmSci. 2004 Feb 09;6(1):E6
15198507
J Pharmacokinet Biopharm. 1975 Apr;3(2):77-97
1173821
Physiol Rev. 1994 Jan;74(1):163-219
8295933
Clin Cancer Res. 2008 Jul 1;14(13):4213-8
18594002
Bull Math Biol. 2007 Jan;69(1):93-117
17024552
Pharm Res. 2010 May;27(5):920-32
20232116
Clin Cancer Res. 2008 Dec 15;14(24):8184-90
19088034
Cancer Res. 1994 Mar 15;54(6):1517-28
8137258
Magn Reson Med. 2000 Aug;44(2):169-73
10918313
Clin Cancer Res. 2008 Sep 15;14(18):5856-63
18794097